Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Non-Randomized Multisite Phase II Trial Combining Bevacizumab, Atezolizumab and Rucaparib for the Treatment of Previously Treated Recurrent and Progressive Endometrial Carcinoma

NCT03694262 is registered in ClinicalTrials.gov with Medical College of Wisconsin as lead sponsor.

NCT NCT03694262
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03694262 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Non-Randomized Multisite Phase II Trial Combining Bevacizumab, Atezolizumab and Rucaparib for the Treatment of Previously Treated Recurrent and Progressive Endometrial Carcinoma
Lead sponsor
Medical College of Wisconsin
Phase
Phase 2
Overall status
Completed
Start date
July 19, 2019
Completion date
March 10, 2026
Enrollment
30 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer, uterine carcinosarcoma